Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Feb, 2015 | Pages:
48 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Bronchopulmonary Dysplasia - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Bronchopulmonary Dysplasia - Pipeline Review, H1 2015', provides an overview of the Bronchopulmonary Dysplasia's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Bronchopulmonary Dysplasia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bronchopulmonary Dysplasia and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Bronchopulmonary Dysplasia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Bronchopulmonary Dysplasia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Bronchopulmonary Dysplasia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Bronchopulmonary Dysplasia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reason to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Bronchopulmonary Dysplasia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Bronchopulmonary Dysplasia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Bronchopulmonary Dysplasia Overview 6 Therapeutics Development 7 Pipeline Products for Bronchopulmonary Dysplasia - Overview 7 Pipeline Products for Bronchopulmonary Dysplasia - Comparative Analysis 8 Bronchopulmonary Dysplasia - Therapeutics under Development by Companies 9 Bronchopulmonary Dysplasia - Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Early Stage Products 12 Bronchopulmonary Dysplasia - Products under Development by Companies 13 Bronchopulmonary Dysplasia - Companies Involved in Therapeutics Development 14 Airway Therapeutics, Inc. 14 Chiesi Farmaceutici SpA 15 Ikaria Inc. 16 MediPost Co., Ltd. 17 Syntrix Biosystems, Inc. 18 Bronchopulmonary Dysplasia - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Drug Profiles 28 AT-100 - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 CG-100 - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 nitric oxide - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Pneumostem - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 R-190 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 R-908 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Small Molecules for Bronchopulmonary Dysplasia - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 SX-682 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Bronchopulmonary Dysplasia - Recent Pipeline Updates 40 Bronchopulmonary Dysplasia - Dormant Projects 41 Bronchopulmonary Dysplasia - Discontinued Products 42 Bronchopulmonary Dysplasia - Product Development Milestones 43 Featured News & Press Releases 43 Sep 14, 2014: MediPost America clears Phase 1/2 IND for the U.S. clinical trial on stem cell drug for lung 43 Aug 12, 2014: MediPost, lung disease stem cell treatment drug 'Pneumostem' application for US clinical trial 43 Feb 06, 2014: Stem cells to treat lung disease in preterm infants 44 Sep 26, 2012: Medipost Receives KFDA Approval For Phase II Clinical Trial Of Lung Disease Medicine Pneumostem 44 May 31, 2012: Medipost Submits Application To KFDA For Pneumostem Clinical Trial 45 Feb 27, 2012: Ikaria Completes Patient Enrollment In Pivotal Phase III Trial For Bronchopulmonary Dysplasia 45 Jan 05, 2011: Ikaria Receives Marketing Exclusivity Extension For Inomax From FDA 46 Appendix 47 Methodology 47 Coverage 47 Secondary Research 47 Primary Research 47 Expert Panel Validation 47 Contact Us 47 Disclaimer 48
List of Tables Number of Products under Development for Bronchopulmonary Dysplasia, H1 2015 7 Number of Products under Development for Bronchopulmonary Dysplasia - Comparative Analysis, H1 2015 8 Number of Products under Development by Companies, H1 2015 9 Comparative Analysis by Late Stage Development, H1 2015 10 Comparative Analysis by Clinical Stage Development, H1 2015 11 Comparative Analysis by Early Stage Development, H1 2015 12 Products under Development by Companies, H1 2015 13 Bronchopulmonary Dysplasia - Pipeline by Airway Therapeutics, Inc., H1 2015 14 Bronchopulmonary Dysplasia - Pipeline by Chiesi Farmaceutici SpA, H1 2015 15 Bronchopulmonary Dysplasia - Pipeline by Ikaria Inc., H1 2015 16 Bronchopulmonary Dysplasia - Pipeline by MediPost Co., Ltd., H1 2015 17 Bronchopulmonary Dysplasia - Pipeline by Syntrix Biosystems, Inc., H1 2015 18 Assessment by Monotherapy Products, H1 2015 19 Number of Products by Stage and Target, H1 2015 21 Number of Products by Stage and Mechanism of Action, H1 2015 23 Number of Products by Stage and Route of Administration, H1 2015 25 Number of Products by Stage and Molecule Type, H1 2015 27 Bronchopulmonary Dysplasia Therapeutics - Recent Pipeline Updates, H1 2015 40 Bronchopulmonary Dysplasia - Dormant Projects, H1 2015 41 Bronchopulmonary Dysplasia - Discontinued Products, H1 2015 42
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
